MLPSC Therapy for Ocular Disease Visual Acuity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular disorders such as age-related macular degeneration and retinitis pigmentosa, which affect visual acuity, are limited in directly improving vision and often rely on anti-VEGF agents that only address neovascularization and fluid accumulation, leaving a need for therapies that can enhance visual acuity directly.
Innovation Solution
Administration of ex vivo expanded allogeneic mesenchymal lineage precursor or stem cells (MLPSCs) to patients with ocular diseases, specifically targeting inflammation or degradation of the optic nerve or photoreceptors, either alone or following anti-VEGF treatment, to improve visual acuity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-VEGF agents are used to treat ocular disorders, then neovascularization and fluid accumulation are reduced, but visual acuity is not directly improved
Solution Approach 1:
The patent combines anti-VEGF agent treatment with MLPSC administration to achieve both neovascularization reduction and direct visual acuity improvement. The treatment protocol integrates monthly anti-VEGF injections with single-dose intravitreal MLPSC injection, creating a synergistic therapy that addresses multiple pathogenic mechanisms simultaneously.
Solution Approach 2:
MLPSCs serve as an intermediary therapeutic mechanism that mediates between the anti-VEGF treatment and visual acuity improvement. The stem cells act as a biological mediator that directly promotes photoreceptor survival, reduces inflammation, and enhances visual function beyond what anti-VEGF agents alone can achieve.
2Reliability
If monthly anti-VEGF treatment is continued for extended periods, then neovascularization is controlled, but treatment burden and cost increase
Solution Approach 1:
The MLPSC administration provides preliminary protective action that reduces the frequency of required anti-VEGF treatments. By establishing long-term protective effects through stem cell-mediated photoreceptor survival and anti-inflammatory actions, the need for continuous monthly injections is reduced, potentially extending treatment intervals.
Solution Approach 2:
The patent aims to establish continuous protective action through MLPSC therapy that reduces the need for repeated anti-VEGF injections. The stem cells provide sustained therapeutic effects including photoreceptor protection, inflammation reduction, and visual acuity maintenance, thereby reducing overall treatment frequency while maintaining disease control.
3Adaptability or versatility
If current treatments focus on neovascularization and fluid accumulation, then vascular pathology is addressed, but photoreceptor degradation is not directly treated
Solution Approach 1:
The MLPSC therapy provides multi-functional treatment capabilities that address both vascular and photoreceptor pathologies. The stem cells exhibit universal therapeutic effects including anti-VEGF activity, anti-inflammatory actions, photoreceptor protection, and visual acuity improvement, making them a versatile treatment that covers multiple disease mechanisms simultaneously.
Solution Approach 2:
The patent applies local quality by targeting specific photoreceptor and retinal structures with MLPSC therapy. The intravitreal administration ensures direct delivery of stem cells to the retina, where they specifically protect photoreceptors and reduce local inflammation, providing localized therapeutic quality that differs from systemic treatments.
Data Source
AI summary
The present disclosure relates to a method of improving visual acuity in a subject suffering from an ocular disease, the method comprising administering to the subject a composition comprising mesenchymal lineage precursor or stem cells (MLPSCs) in an amount sufficient to improve visual acuity.